PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• PTC Therapeutics, Inc. has received an average rating of "Moderate Buy" from 15 brokerages, with nine analysts recommending a buy, five a hold, and one a sell.
• The company's stock price target has been set at an average of $69.00, with recent analyst reports ranging from $42.00 to $73.00.
• In its latest earnings report, PTC Therapeutics beat earnings estimates with a loss of ($0.83) per share and reported revenue of $178.88 million, although revenue was down 4.2% compared to the same quarter last year.

PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fifteen brokerages that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $69.00.

A number of research analysts recently weighed in on the stock. Wall Street Zen downgraded shares of PTC Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Saturday, August 9th. Robert W. Baird set a $70.00 price objective on shares of PTC Therapeutics in a research report on Friday, August 8th. Weiss Ratings reissued a "hold (c-)" rating on shares of PTC Therapeutics in a research report on Wednesday, October 8th. Wells Fargo & Company initiated coverage on shares of PTC Therapeutics in a research report on Monday, October 20th. They issued an "overweight" rating and a $73.00 price objective for the company. Finally, Barclays lifted their price objective on shares of PTC Therapeutics from $42.00 to $46.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 29th.

PTC Therapeutics Trading Down 0.6%

PTC Therapeutics stock opened at $66.40 on Friday. The company has a market cap of $5.27 billion, a P/E ratio of 9.53 and a beta of 0.55. PTC Therapeutics has a 1-year low of $35.95 and a 1-year high of $69.48. The company has a fifty day simple moving average of $59.41 and a 200 day simple moving average of $51.85.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, beating analysts' consensus estimates of ($1.07) by $0.24. The business had revenue of $178.88 million during the quarter, compared to the consensus estimate of $173.01 million. PTC Therapeutics had a net margin of 35.65% and a negative return on equity of 106.31%. The firm's revenue for the quarter was down 4.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.29) earnings per share. PTC Therapeutics has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that PTC Therapeutics will post -4.52 EPS for the current year.

Insider Buying and Selling

In other news, VP Mark Elliott Boulding sold 24,585 shares of PTC Therapeutics stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $61.34, for a total value of $1,508,043.90. Following the completion of the transaction, the vice president owned 103,901 shares of the company's stock, valued at $6,373,287.34. This trade represents a 19.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Emma Reeve sold 25,562 shares of PTC Therapeutics stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $65.96, for a total transaction of $1,686,069.52. Following the sale, the director directly owned 10,332 shares of the company's stock, valued at $681,498.72. The trade was a 71.22% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 249,735 shares of company stock worth $15,467,670. Corporate insiders own 5.50% of the company's stock.

Institutional Trading of PTC Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Wealth Enhancement Advisory Services LLC bought a new stake in shares of PTC Therapeutics during the 1st quarter worth about $595,000. Allspring Global Investments Holdings LLC bought a new stake in shares of PTC Therapeutics during the 1st quarter worth about $524,000. Sector Gamma AS boosted its holdings in shares of PTC Therapeutics by 41.4% during the 1st quarter. Sector Gamma AS now owns 92,250 shares of the biopharmaceutical company's stock worth $4,701,000 after buying an additional 27,000 shares during the period. Deutsche Bank AG boosted its holdings in shares of PTC Therapeutics by 262.1% during the 1st quarter. Deutsche Bank AG now owns 341,724 shares of the biopharmaceutical company's stock worth $17,414,000 after buying an additional 247,346 shares during the period. Finally, Cerity Partners LLC bought a new stake in shares of PTC Therapeutics during the 1st quarter worth about $641,000.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.